ArticleShock (Augusta, Ga.)2026
Prognostic Significance of the Prothrombin Time-International Normalized Ratio to Albumin Ratio in Cancer Patients with Complication of Sepsis: A Retrospectively Cohort Study.
Article in Shock (Augusta, Ga.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccumulating evidence supports the use of the prothrombin time-international normalized ratio-to-albumin ratio (PTAR) as a prognostic biomarker in various diseases. This study evaluated whether PTAR, an easily measurable index, predicts short- and long-term all-cause mortality in cancer patients with sepsis (cancer sepsis).
methodsThis retrospective cohort study used data from 1,584 adult cancer-sepsis patients in the intensive care unit from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database (v3.1) and 82 patients from a Chinese tertiary oncology hospital. Mortality at 28 and 365 days was analyzed using multivariable Cox models, restricted cubic splines, Kaplan-Meier curves, and subgroup analyses. Discriminatory performance was assessed with the area under the receiver operating characteristic curve (AUC), comparing PTAR with the Sequential Organ Failure Assessment (SOFA) score, international normalized ratio (INR), and serum albumin (ALB). AUC differences were tested using DeLong's test.
resultsIn the MIMIC-IV cohort, patients in the highest PTAR quartile (Q4) had significantly higher risks of 28-day (adjusted heart rate = 2.038) and 365-day mortality (adjusted heart rate = 1.615). PTAR showed superior discrimination compared with the SOFA score and INR at both time points. In the Chinese cohort, PTAR also predicted 28-day mortality (adjusted heart rate = 4.682), with better AUC (0.721) than SOFA (0.564).
conclusionsPTAR at intensive care unit admission independently predicts 28-day mortality in cancer patients with sepsis in both the MIMIC-IV and Chinese cohorts, outperforming SOFA and INR. The 365-day mortality was validated only in the MIMIC-IV cohort, where PTAR demonstrated stronger predictive performance compared with INR and SOFA. Therefore, PTAR can serve as a complementary biomarker to be used in conjunction with existing clinical scoring systems and laboratory indicators, providing additional risk assessment information for cancer-sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.